GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (NAS:ORMP) » Definitions » Shiller PE Ratio

ORMP (Oramed Pharmaceuticals) Shiller PE Ratio : (As of Apr. 26, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Oramed Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Oramed Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Oramed Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals Shiller PE Ratio Chart

Oramed Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Oramed Pharmaceuticals Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oramed Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Oramed Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oramed Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oramed Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Oramed Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Oramed Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Oramed Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.26/133.1571*133.1571
=-0.260

Current CPI (Dec. 2024) = 133.1571.

Oramed Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201502 -0.150 99.032 -0.202
201505 -0.150 100.333 -0.199
201508 -0.190 100.548 -0.252
201511 -0.210 100.135 -0.279
201602 -0.140 100.040 -0.186
201605 -0.150 101.355 -0.197
201608 -0.370 101.617 -0.485
201611 -0.200 101.829 -0.262
201702 -0.240 102.779 -0.311
201705 -0.150 103.256 -0.193
201708 -0.200 103.587 -0.257
201711 -0.180 104.072 -0.230
201802 -0.200 105.052 -0.254
201805 -0.300 106.148 -0.376
201808 -0.180 106.383 -0.225
201811 -0.250 106.338 -0.313
201902 -0.210 106.649 -0.262
201905 -0.230 108.048 -0.283
201908 -0.130 108.245 -0.160
201911 -0.150 108.519 -0.184
202002 -0.210 109.139 -0.256
202005 -0.100 108.175 -0.123
202008 -0.120 109.662 -0.146
202011 -0.230 109.793 -0.279
202102 -0.170 110.968 -0.204
202105 -0.170 113.576 -0.199
202108 -0.210 115.421 -0.242
202111 -0.220 117.269 -0.250
202203 -0.270 121.301 -0.296
202206 -0.270 125.017 -0.288
202209 -0.180 125.227 -0.191
202212 -0.220 125.222 -0.234
202303 -0.080 127.348 -0.084
202306 -0.030 128.729 -0.031
202309 -0.080 129.860 -0.082
202312 0.330 129.419 0.340
202403 0.040 131.776 0.040
202406 0.220 132.554 0.221
202409 -0.480 133.029 -0.480
202412 -0.260 133.157 -0.260

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Oramed Pharmaceuticals  (NAS:ORMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Oramed Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oramed Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Executives
Benjamin Shapiro director 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Nadav Kidron director, 10 percent owner 142 W. 57TH ST., NEW YORK NY 10019
Yadin Rozov director 9 TERRACE CIRCLE, ARMONK NY 10504
Miriam Kidron director 2 ELZA STREET, JERUSALEM L3 93706
Michael Rabinowitz officer: Chief Commercial Officer 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK NY 10036
Arie Mayer director MORAN 16, KFAR SABA L3 4428890
Netanel Derovan officer: Chief Legal Officer 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
David Silberman officer: Chief Financial Officer 20 MAMILLA AVENUE, JERUSALEM L3 9414904
Kevin Rakin director 36 CHURCH LANE, WESTPORT CT 06880
Michael Rabinowitz officer: Chief Commercial Officer MAXIM GROUP, LLC, 405 LEXINGTON AVENUE, NEW YORK NY 10174
Leonard Sank director 3 BLAIR ROAD, CAPE TOWN T3 8005
Gao Xiaoming director 11F. NO. 266 HANKOU ROAD, HUANGPU DISTRICT, SHANGHAI F4 2000001
Avraham Gabay officer: CFO, Treasurer and Secretary 2/4 HIGH-TECH PARK, P.O. BOX 39098, JERUSALEM L3 91390
Mark Daniel Hasleton officer: VP Business Development 13, HIBAT ZION, RAANANA, RAANANA L3 4338111
Aviad Friedman director HADASSA 6, TEL AVIV L3 6451306